Pfizer chided by China drug regulator; Vet drug fees raised; Sagent expands recall;

@FiercePharma: Come join our new LinkedIn group to connect with others in the industry and read, share and discuss the latest news. Join the group | Follow @FiercePharma

@EricPFierce: FDA approves Amgen's Xgeva for bone tumor. It is a small market for a key drug that is not yet a blockbuster. Press release | Follow @EricPFierce

@CarlyHFierce: Gleevec patent battle between Novartis and Sun Pharma moving to the U.S. Yesterday's story | Follow @CarlyHFierce

> Sagent Pharmaceuticals ($SGNT) has expanded its voluntary recall of paralyzing agent Vecuronium Bromide, manufactured for it by MN Pharmaceuticals, to all 18 lots after high levels of impurities were found in three lots. Notice

> Europe's drugs agency warned on Friday that use of the common painkiller diclofenac, especially in high doses, carries extra heart attack risks, which should be taken into consideration by doctors prescribing the drug. Story

> The FDA is looking further at using database mining to assess post0market dangers, this time targeting inpatient and emergency settings. Story

> China's drug regulator has told Pfizer ($PFE) it needs to do a better job with quality, noting 33 recalls issued by the U.S.-based drug maker over the past four years--two within the past two months. Report

> A draft report from the U.S. House of Representatives raises concerns about the FDA and calls for, among other things, greater transparency in how it operates. Blog post

Medical Device News

@FierceMedDev: MC10 pushes wearable sensors with Medtronic co-sign. News | Follow @FierceMedDev

@DamianFierce: ICYMI: Startup NeuroTronik raised $13.1M to develop a neuromodulation solution for heart failure. News | Follow @DamianFierce

@MarkHFierce: Nearly $10M in new financing will help Veniti gain CE marking for vein treatment devices. Report | Follow @MarkHFierce

> AdvaMed to FDA: 510(k) rules are fine as they are. Story

> Japan prepares to cover cancer-related breast implants. Item

> Myriad's Supreme Court loss is Quest Diagnostics' gain. More

Biotech News

@FierceBiotech: From FierceBiomarkers.com : Brain scan may provide biomarker guideposts to ideal depression treatment. Article | Follow @FierceBiotech

 @JohnCFierce: Look for early competition on hep C: Gilead 1, AbbVie in photo finish 2; BMS 3. As ranked by Bloomberg. Report | Follow @JohnCFierce

@RyanMFierce: AbbVie: We can beat Gilead in blockbuster hep C race. Report | Follow @RyanMFierce

 @EmilyMFierce:  | Follow @EmilyMFierce

> AbbVie: We can beat Gilead in blockbuster hep C race. Story

> Elan shares jump on news of sale process for the biotech. Report

> Eli Lilly racks up another Alzheimer's failure after BACE drug sparks safety fears. Article

And Finally... In what might be termed the administration's pet project, U.S. President Barack Obama has signed into law legislation that increases fees on the veterinary pharmaceutical industry with the idea of speeding drugs to market. Story

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.